SK Hynix vs Vir Biotechnology Inc. Common Stock — how do they compare? SK Hynix trades at $137.9 (market cap $771.50B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: SK Hynix is far larger — about 438.4× Vir Biotechnology Inc. Common Stock's market cap, and SK Hynix pays a 0.07% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SK Hynix for 12 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SKHY | VIR | |
|---|---|---|
Market Cap | $771.50B | $1.76B |
Volume | 22,899,644 | 2,764,948 |
Sector | Technology | Health |
52-Week High | $198.63 | $11.78 |
52-Week Low | $126.79 | $5.12 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $721.62B | $1.32B |
Dividend Yield | 0.07% | — |
Signals from Pluang's Aura AI — not financial advice
SKHY trades at $157.06, down 3.15% amid a sector-wide tech selloff driven by Fed rate hike concerns and competitive threats from Chinese chipmaker CXMT. The stock shows strong fundamentals with a P/E of 9.27, net income margin of 85.62%, and consistent earnings beats. Technical indicators are bearish with moving averages signaling selling pressure, though oscillators suggest potential oversold conditions. Recent news highlights AI memory demand growth but also increased competition risks.
Despite near-term volatility, SKHY maintains robust profitability and analyst consensus remains bullish with a $242 price target representing 54% upside. Key risks include Chinese competition and macroeconomic pressures, but the company's leadership in AI memory and strong financial metrics support long-term growth potential for patient investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →